Nurix Therapeutics, Inc. filed a current report on November 3, 2026, disclosing that collaboration partner Sanofi S.A. notified the company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program entirely.

Key Highlights

  • Program terminated: Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272 and to terminate the SAR448272 program.
  • Asset description: SAR448272 is described in the filing as an oral STAT6 degrader developed under the Sanofi Collaboration.
  • Milestone and royalty loss: As a result of Sanofi's decision, Nurix does not expect to receive any future development, regulatory, or commercial milestone payments or royalties tied to the SAR448272 program.
  • Remaining collaboration intact: Nurix disclosed it remains eligible to receive milestone payments and royalties for other previously announced licensed programs under the Sanofi Collaboration that Sanofi may at its discretion advance further.
  • Signing authority: The report was signed by Christine Ring, Ph.D., J.D., Chief Legal Officer of Nurix Therapeutics.

Nurix Loses SAR448272 Milestone Stream After Sanofi Discontinuation

Nurix Therapeutics (NASDAQ:NRIX), a biopharmaceutical company based in Brisbane, California that focuses on targeted protein degradation, disclosed that Sanofi S.A. informed it of the decision to stop the Phase 1 first-in-human clinical trial of SAR448272 and to fully terminate that program. The notification and the company's announcement both occurred on November 3, 2026, the same date the current report was filed with the Securities and Exchange Commission under Item 8.01 (Other Events).

According to the filing, the financial consequence of Sanofi's decision is that Nurix "does not expect to receive any of the future development, regulatory and commercial milestone payments or royalties for which it was eligible under the Company's collaboration with Sanofi" with respect to the SAR448272 program. SAR448272 had been progressing as an oral STAT6 degrader, a modality central to Nurix's platform of leveraging the ubiquitin-proteasome system to degrade disease-causing proteins.

The filing also clarified the status of the broader Sanofi Collaboration. Nurix stated that it "remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the Sanofi Collaboration that Sanofi may at its discretion develop further into clinical candidates." The filing noted that Sanofi retains discretion over whether to advance those remaining programs, which the company identified as a risk factor in its cautionary language. The forward-looking statements in the report are described by the company as subject to risks detailed in its Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2026, and other regulatory filings.

What Was Disclosed

Nurix Therapeutics reported that Sanofi terminated the SAR448272 oral STAT6 degrader program and its associated Phase 1 trial, eliminating Nurix's eligibility for related milestone payments and royalties, while leaving other Sanofi Collaboration programs potentially intact.